دورية أكاديمية

The effectiveness of antioxidant vitamins C and E in reducing myocardial infarct size in patients subjected to percutaneous coronary angioplasty (PREVEC Trial): study protocol for a pilot randomized double-blind controlled trial

التفاصيل البيبلوغرافية
العنوان: The effectiveness of antioxidant vitamins C and E in reducing myocardial infarct size in patients subjected to percutaneous coronary angioplasty (PREVEC Trial): study protocol for a pilot randomized double-blind controlled trial
المؤلفون: Rodrigo Salinas, Ramón, Hasson, Daniel, Prieto Domínguez, Juan, Dussaillant Nielsen, Gastón, Ramos, Cristóbal, León, Lucio, Gárate, Javier, Gormaz, Juan, Valls, Nicolás
بيانات النشر: BioMed Central
سنة النشر: 2014
المجموعة: Universidad de Chile: Repositorio académico
مصطلحات موضوعية: Percutaneous coronary angioplasty
الوصف: Artículo de publicación ISI ; Background: Acute myocardial infarction (AMI) is the leading cause of mortality worldwide. Oxidative stress has been involved in the ischemia-reperfusion injury in AMI. It has been suggested that reperfusion accounts for up to 50% of the final size of a myocardial infarct, a part of the damage likely to be prevented.Therefore, we propose that antioxidant reinforcement through vitamins C and E supplementation should protect against the ischemia-reperfusion damage, thus decreasing infarct size. The PREVEC Trial (Prevention of reperfusion damage associated with percutaneous coronary angioplasty following acute myocardial infarction) seeks to evaluate whether antioxidant vitamins C and E reduce infarct size in patients subjected to percutaneous coronary angioplasty after AMI. Methods/Design: This is a randomized, 1:1, double-blind, placebo-controlled clinical trial. The study takes place at two centers in Chile: University of Chile Clinical Hospital and San Borja Arriarán Clinical Hospital. The subjects will be 134 adults with acute myocardial infarction with indication for percutaneous coronary angioplasty. This intervention is being performed as a pilot study, involving high-dose vitamin C infusion plus oral administration of vitamin E (Vitamin-treatment group) or placebo (Control group) during the angioplasty procedure. Afterward, the Vitamin-treatment group receives oral doses of vitamins C and E, and the Control group receives placebo for 84 days after coronary angioplasty. Primary outcome is infarct size, assessed by cardiac magnetic resonance (CMR), measured 6 and 84 days after coronary angioplasty. Secondary outcomes are ejection fraction, measured 6 and 84 days after coronary angioplasty with CMR, and biomarkers for oxidative stress, antioxidant status, heart damage, and inflammation, which will be measured at baseline, at the onset of reperfusion, 6 to 8 hours after revascularization, and at hospital discharge. Discussion: The ischemia-reperfusion event occurring during ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: application/pdf
اللغة: English
العلاقة: Trials 2014, 15:192; https://repositorio.uchile.cl/handle/2250/129564Test
DOI: 10.1186/1745-6215-15-192
الإتاحة: https://doi.org/10.1186/1745-6215-15-192Test
https://repositorio.uchile.cl/handle/2250/129564Test
حقوق: Attribution-NonCommercial-NoDerivs 3.0 Chile ; http://creativecommons.org/licenses/by-nc-nd/3.0/clTest/
رقم الانضمام: edsbas.68BD4C7E
قاعدة البيانات: BASE